Announcements Trials
Browse Landscape

Phase

Phase 3 5Phase 4 4Phase 2 3Phase NA 1Phase 1 1

Status

Completed 3

Sponsor Class

OTHER 1NETWORK 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Endocrine 7Gastrointestinal 5Thoracic 4NET 3Gynecologic 2Genitourinary 2CNS 2Sarcoma 1Other hematologic neoplasm 1Other 1Lymphoid 1Head & Neck 1Breast 1

Conditions

Neuroendocrine Tumors 3Carcinoma, Islet Cell 2Vipoma 1Somatostatinoma 1Neoplasms 1Neoplasm Metastasis 1Insulinoma 1Glucagonoma 1Gastrinoma 1Carcinoma 1Carcinoid Tumor 1Adenoma, Islet Cell 1

Interventions

lutetium Lu 177 dotatate 18Everolimus 13Temozolomide 12Nivolumab 10pembrolizumab 9cabozantinib 8Capecitabine 8Sunitinib 7lenvatinib 5Magnetic Resonance Spectroscopy 5Etoposide 5lanreotide 4gallium Ga 68 dotatate 4Specimen Handling 4Ipilimumab 4Cisplatin 4Carboplatin 4177Lu-octreotide, DOTA(0)-Tyr(3)- 4telotristat ethyl 3surufatinib 3pazopanib 3avelumab 3Octreotide 3Injections 3Fluorodeoxyglucose F18 3Cyclophosphamide 3Bevacizumab 3sintilimab 2fosbretabulin 2fludarabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Octreotide × NET × Clear all
NCT00427349 2023-07-05

AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

Eastern Cooperative Oncology Group

Phase 2 Completed
46 enrolled 7 charts
EndocrineNET

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

NCT04129255 2020-09-10

CSMS99

National Cancer Institute, Naples

Phase 2 Completed
34 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT00781911 2019-09-20

A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer

Eli Lilly and Company

Phase 2 Completed
43 enrolled 12 charts
EndocrineNET

Carcinoid Tumor, Carcinoma, Neoplasm Metastasis, Carcinoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡